MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

Bookmark and Share
Published: 9 Jul 2020
Views: 555
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA

Dr Luciano Costa speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He presents the updated results from the MASTER study, which investigated the combination of daratumumab, carlfizomib, lenalidomide and dexamethasone (Dara-KRd) to treat patients with newly-diagnosed multiple myeloma (NDMM), with the use of MRD-guided post autologous transplantation (AHCT) consolidation, and MRD surveillance.

Dr Costa outlines the study design, main findings and conclusions achieved with the use of this approach in this patient population. 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.